Ganetespib, an HSP90 inhibitor, targets several oncogenic proteins in prostate cancer cells, including AR and PI3K/AKT pathway; this drug, combined with castration, induced more pronounced tumor regressions and delayed castration resistance relative to either monotherapy [669]. Here, AKT1 is linked to prostate cancer.